[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-disorders-in-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-disorders-in-pregnancy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100646800","early-phase-1-breathing-for-two-inspiratory-muscle-strength-training-for-supporting-healthy-blood-pressure-in-pregnancy-100646800",false,"NCT07687745","Breathing for Two: Inspiratory Muscle Strength Training for Supporting Healthy Blood Pressure in Pregnancy","Inclusion Criteria:\n\n* Female sex\n* Pregnant (32 to 34 weeks of gestation, confirmed by ultrasound, at the time of first training session, eligible patients may consent\u002Fenrolled earlier in pregnancy)\n* Singleton pregnancy\n* Age 18 to 55\n* Able to read English and provide consent\n* Possess smartphone for syncing the AiroFit and Omron devices using Bluetooth and completing online surveys\n* Smartphone updated to iOS 12+ or Android 11+\n* No contraindication for moderate exercise at time of enrollment\n* Not planning delivery for at least one month at time of enrollment (\\\u003C 38 weeks of gestation)\n* Willing to adhere to AiroFit device use throughout study period\n* Must already be scheduled, or in the process of scheduling, for weekly NST appointments by 32 to 34 weeks gestational age (per provider order \u002F due to obstetric indication)\n\nLower-Risk Pregnancy Cohort Inclusion Criteria:\n\n* No history or evidence of hypertensive disorders of pregnancy\n* May be undergoing antenatal testing for:\n* Conception via in vitro fertilization, BMI ≥ 35, an advanced maternal age (age \\>\u002F=35), or other condition not listed in exclusion criteria or 'higher risk for HDP group' but is recommended for antenatal testing.\n\nHigher-Risk Pregnancy Cohort Inclusion Criteria:\n\n* Conditions associated with higher risk of developing HDP, including:\n* Gestational diabetes mellitus, chronic hypertension, gestational hypertension, or a history of preeclampsia in a previous pregnancy\n\nExclusion Criteria:\n\n* Younger than 18 or older than 55 years of age\n* Multiple gestation (twin or higher-order pregnancy)\n* Fetal chromosomal abnormalities or major anatomical anomalies\n* Planning to deliver earlier than 38 weeks or within 4 weeks of study enrollment\n* Any contraindication for moderate exercise (e.g., cardiomyopathy, congenital cardiac conditions)\n* Deep vein thrombosis\n* Complications in current pregnancy including intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, or severe-range blood pressures (\\>\u002F=160\u002F110 or \\\u003C100\u002F60)\n* Active vaginal bleeding, or history of coagulopathy\n* Placenta previa or other placental abnormalities (including placental cyst or abruption)\n* Signs of labor\n* Current substance use disorder\n* History of neurological, respiratory, head\u002Fneck, or thoracic surgeries, or conditions such as collapsed lung or perforated eardrum\n* Individuals with any of the following:\n* Chronic obstructive pulmonary disorder (COPD)\n* Severe asthma\n* Severe ischemic heart disease\n* Left-sided heart failure\n* Chronic laryngitis, chronic bronchitis, emphysema, pneumonia\n* Latent or active tuberculosis\n* Chronic cough\n* Neurological problems (e.g. seizure disorder)\n* Severe scoliosis with no history of surgical correction or management.\n* Organ transplant\n* HIV or other immunocompromising conditions\n* Autoimmune disease with possible vascular complications (e.g. Lupus)\n* Significant respiratory compromise (e.g., severe dyspnea, O₂ saturation \\\u003C95%, uncontrolled asthma, history of pneumothorax)",true,"FEMALE","18 Years","55 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This is an interventional study that will test whether a breathing exercise called Inspiratory Muscle Strength Training (IMST) can safely and effectively lower blood pressure during late pregnancy. The goal is to see if a home-based breathing training can help prevent or reduce high blood pressure disorders in pregnancy. The main objectives are to make sure the training is safe and tolerable for pregnant women and to examine blood pressure and blood vessel health. Participants in their third trimester will be randomly assigned to either do moderate resistance IMST or a minimal resistance sham IMST, for 5 to 8 minutes a day over six weeks.",[27,28,29,30],"Hypertension Disorders in Pregnancy","Blood Pressure Measurement in Pregnancy","Inspiratory Strength Training (IST)","Pregnancy",[32,33,34,35,36,37],"pregnancy","blood pressure","hypertensive disorders of pregnancy","imst","hdp","inspiratory muscle strength training","RECRUITING","2026-07-01",{"date":41,"type":42},"2026-07-07","ACTUAL",{"date":44,"type":42},"2026-06-08",{"date":46,"type":21},"2027-09-30",{"name":48,"class":49},"University of Arizona","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100402421","vascular-biomarkers-predictive-of-the-progression-from-hypertensive-disorders-in-pregnancy-to-preeclampsia-in-pregnant-women-100402421","NCT04520048","Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","Exploratory Study. Endothelial Function and Vascular-tropic Biomarkers: Predictive Indicators of the Progression of Hypertensive Disorders in Pregnancy to Pre-eclampsia?","BIOVASC-PreHTA","Inclusion Criteria:\n\n* Patients with a hypertension disorder in pregnancy and\u002For preeclampsia from the 20th amenorrhea week until the 26th ± 2 amenorrhea week.\n* Age between 18 and 40 years old.\n* Having given written consent.\n* Patients affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Presence of pathologies interfering in a major way with vascular parameters: known multicomplicated diabetes treated before pregnancy, hypercholesterolemia known (or LDL\\>130 mg\u002Fdl), multicomplicated connectivitis, proven cardiovascular disease (ischemic heart disease, stroke, arteriopathy of the lower limbs, heart failure), pre-existing known renal failure (serum creatinine \\>125 µmol\u002FL) and\u002For pre-existing proteinuria ≥ 300 mg\u002F24h).\n* Cardiac arrhythmia.\n* Hepatitis C, HIV infection (assay performed within 6 months prior to diagnosis of pre-eclampsia).\n* Recent history of venous (pulmonary embolism, phlebitis) or arterial (myocardial infarction, unstable angina, stroke, transient ischemic attack), thrombotic event ≤ 3 months.\n* Patient already engaged in a therapeutic protocol.\n* Patients under legal protective measures.\n* Patients receiving State Medical Assistance.","40 Years",{"count":61,"type":21},110,[63],"NA","Hypertension during pregnancy remains a leading cause of maternal and fetal morbidity and mortality. The frequency (5 to 10% of pregnancies) and potential severity of these diseases, both for the mother and the child, are reasons for standardizing and optimizing medical practices.\n\nThe cause of hypertension during pregnancy is quite complex, as it depends on a number of factors. Among the hypertensive disorders in pregnancy (HDP), the pathophysiology of pre-eclampsia (one of the most studied in terms of severity) remains poorly understood. The evolution of international guidelines in recent years has made it possible to distinguish various HDP, but schematically we distinguish two main entities by the existence of proteinuria from and after the 20th week of amenorrhea and by maternal-fetal complications, more serious in pre-eclampsia than in gestational hypertension.\n\nAcute placental vasculature and blood flow abnormalities were observed during gestational hypertension and preeclampsia, and maybe due to generalized vascular endothelial activation and vasospasm resulting in systemic hypertension and organ hypoperfusion. Endothelial dysfunction (ED) and abnormal expression of several specific blood biomarkers are now well accepted as characteristics of preeclampsia as a leader.\n\nHowever, the progression of any HDP to preeclampsia is possible, but difficult to predict. By way of example, among between 15 and 40 % of gestational hypertension cases progress to preeclampsia, suggesting that it is the same worsening disease.\n\nED could be pre-existing (chronic, white-coat or masked hypertension) but also at the origin of gestational hypertension (unclassified hypertension, transient pregnancy hypertension), and subsequent development of preeclampsia through an imbalance between pro- and anti-angiogenic factors.\n\nAn imbalance of pro-angiogenic and anti-angiogenic proteins can testify to ED, as can adequate levels of endothelial microparticles.\n\nThe main objective of this research is to assess the presence of urinary endothelial microparticles in stable pregnant women with hypertensive disorder of pregnancy as a marker for the occurrence of pre-eclampsia during pregnancy.",[27,66,67],"Gestational Hypertension","Pre-Eclampsia",[69,70,71,72,73,74,75,76,77,78],"Hypertension disorders in pregnancy","Gestational hypertension","Pre-eclampsia","Urinary endothelial microparticules","Endothelial dysfunction","Angiogenic biomarkers","Soluble Fms-like- tyrosine kinase 1","Placental Growth Factor","Vascular Endothelial Growth Factor","Microcirculation","2025-09-05",{"date":81,"type":42},"2025-09-12",{"date":83,"type":42},"2023-08-11",{"date":85,"type":21},"2026-12",{"name":87,"class":49},"Assistance Publique - Hôpitaux de Paris",3]